View Item 

Show simple item record

Genomic and clinical characterization of stromal infiltration markers in prostate cancer
dc.contributor.authorMahal, Brandon A.
dc.contributor.authorAlshalalfa, Mohammed
dc.contributor.authorZhao, Shuang G.
dc.contributor.authorBeltran, Himisha
dc.contributor.authorChen, William S.
dc.contributor.authorChipidza, Fallon
dc.contributor.authorDavicioni, Elai
dc.contributor.authorKarnes, R. Jeffrey
dc.contributor.authorKu, Sheng‐yu
dc.contributor.authorLotan, Tamara L.
dc.contributor.authorMuralidhar, Vinayak
dc.contributor.authorRebbeck, Timothy R.
dc.contributor.authorSchaeffer, Edward M.
dc.contributor.authorSpratt, Daniel E.
dc.contributor.authorFeng, Felix Y.
dc.contributor.authorNguyen, Paul L.
dc.date.accessioned2020-03-17T18:34:59Z
dc.date.availableWITHHELD_14_MONTHS
dc.date.available2020-03-17T18:34:59Z
dc.date.issued2020-04-01
dc.identifier.citationMahal, Brandon A.; Alshalalfa, Mohammed; Zhao, Shuang G.; Beltran, Himisha; Chen, William S.; Chipidza, Fallon; Davicioni, Elai; Karnes, R. Jeffrey; Ku, Sheng‐yu ; Lotan, Tamara L.; Muralidhar, Vinayak; Rebbeck, Timothy R.; Schaeffer, Edward M.; Spratt, Daniel E.; Feng, Felix Y.; Nguyen, Paul L. (2020). "Genomic and clinical characterization of stromal infiltration markers in prostate cancer." Cancer (7): 1407-1412.
dc.identifier.issn0008-543X
dc.identifier.issn1097-0142
dc.identifier.urihttps://hdl.handle.net/2027.42/154519
dc.publisherWiley Periodicals, Inc.
dc.subject.otherstromal infiltration
dc.subject.otherDecipher
dc.subject.othergenomics
dc.subject.othertumor microenvironment
dc.subject.otherprostatic neoplasms
dc.titleGenomic and clinical characterization of stromal infiltration markers in prostate cancer
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154519/1/cncr32688_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/154519/2/cncr32688.pdf
dc.identifier.doi10.1002/cncr.32688
dc.identifier.sourceCancer
dc.identifier.citedreferenceTyekucheva S, Bowden M, Bango C, et al. Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun. 2017; 8: 420.
dc.identifier.citedreferenceSiegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7 â 34.
dc.identifier.citedreferenceHanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646 â 674.
dc.identifier.citedreferenceStraussman R, Morikawa T, Shee K, et al. Tumour microâ environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012; 487: 500 â 504.
dc.identifier.citedreferenceKalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016; 16: 582 â 598.
dc.identifier.citedreferenceZhao SG, Chen WS, Das R, et al. Clinical and genomic implications of luminal and basal subtypes across carcinomas. Clin Cancer Res. 2019; 25: 2450 â 2457.
dc.identifier.citedreferenceMuralidhar V, Zhang J, Wang Q, et al. Genomic validation of 3â tiered clinical subâ classification of highâ risk prostate cancer. Int J Radiat Oncol Biol Phys. 2019; 105: 621 â 627.
dc.identifier.citedreferenceBaca SC, Prandi D, Lawrence MS, et al. Punctuated evolution of prostate cancer genomes. Cell. 2013; 153: 666 â 677.
dc.identifier.citedreferenceYoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4: 2612.
dc.identifier.citedreferenceZhao SG, Chang SL, Erho N, et al. Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol. 2017; 3: 1663 â 1672.
dc.identifier.citedreferenceZhao SG, Chang SL, Spratt DE, et al. Development and validation of a 24â gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. Lancet Oncol. 2016; 17: 1612 â 1620.
dc.identifier.citedreferenceNakagawa T, Kollmeyer TM, Morlan BW, et al. A tissue biomarker panel predicting systemic progression after PSA recurrence postâ definitive prostate cancer therapy. PLoS One. 2008; 3: e2318.
dc.identifier.citedreferenceKarnes RJ, Bergstralh EJ, Davicioni E, et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol. 2013; 190: 2047 â 2053.
dc.identifier.citedreferenceD’Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998; 280: 969 â 974.
dc.identifier.citedreferenceRoss AE, Johnson MH, Yousefi K, et al. Tissueâ based genomics augments postâ prostatectomy risk stratification in a natural history cohort of intermediateâ and highâ risk men. Eur Urol. 2016; 69: 157 â 165.
dc.identifier.citedreferenceErho N, Crisan A, Vergara IA, et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One. 2013; 8: e66855.
dc.identifier.citedreferenceAran D, Sirota M, Butte AJ. Systematic panâ cancer analysis of tumour purity. Nat Commun. 2015; 6: 8971.
dc.identifier.citedreferenceMahal BA, Alshalalfa M, Spratt DE, et al. Prostate cancer genomicâ risk differences between Africanâ American and white men across Gleason scores. Eur Urol. 2019; 75: 1038 â 1040.
dc.identifier.citedreferenceAlshalalfa M, Nguyen PL, Beltran H, et al. Transcriptomic and clinical characterization of neuropeptide Y expression in localized and metastatic prostate cancer: identification of novel prostate cancer subtype with clinical implications. Eur Urol Oncol. 2019; 2: 405 â 412.
dc.identifier.citedreferenceSpratt DE, Yousefi K, Deheshi S, et al. Individual patientâ level metaâ analysis of the performance of the Decipher genomic classifier in highâ risk men after prostatectomy to predict development of metastatic disease. J Clin Oncol. 2017; 35: 1991 â 1998.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cncr32688_am.pdf
Size:
183.2KB
Format:
PDF
View/Open
Name:
cncr32688.pdf
Size:
478.6KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.